CORRECTION FROM SOURCE: BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
Marketwired - Wed May 13, 3:22PM CDT
A correction from source is being issued with respect to the BioSyent Inc. release that was disseminated May 13, 2015 at 08:00 ET. The third bullet point previously compared Q1 2015 with Q1 2013 as opposed to Q1 2014. The correct version follows:
RX.VN: 7.570 (-0.250)
BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
Marketwired - Wed May 13, 7:02AM CDT
BioSyent Inc. ("BioSyent"
RX.VN: 7.570 (-0.250)
BioSyent to Present at the 2015 Bloom Burton & Co. Healthcare Investor Conference
Marketwired - Fri May 01, 3:02PM CDT
BioSyent Inc. ("BioSyent"
RX.VN: 7.570 (-0.250)
BioSyent Comments on Recent Market Activity
Marketwired - Fri Apr 10, 7:01AM CDT
BioSyent Inc. ("BioSyent"
RX.VN: 7.570 (-0.250)
BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products Using the Patented Aguettant System(R)
Marketwired - Tue Feb 03, 7:05AM CST
BioSyent Inc. ("BioSyent"
RX.VN: 7.570 (-0.250)
BioSyent Pharma Launches New Proktis-M(R) Suppositories
Marketwired - Mon Nov 24, 7:07AM CST
BioSyent Inc. ("BioSyent"
RX.VN: 7.570 (-0.250)
BioSyent Releases Q3 and Nine Month Results-Q3 Sales Increase 56%, Net Income Up 64%; Nine Month Sales Up 62%, Net Income Up 75%
Marketwired - Mon Oct 20, 7:06AM CDT
BioSyent Inc. ("BioSyent"
RX.VN: 7.570 (-0.250)
BioSyent Releases Q2 and Six Month Results-Q2 Sales Increase 72%, Net Income After Tax Up 112%
Marketwire - Thu Aug 21, 7:03AM CDT
BioSyent Inc. ("BioSyent"
RX.VN: 7.570 (-0.250)
BioSyent Pharma Signs Exclusive Licensing and Distribution Agreement For New Urgent Care Drug Product
Marketwire - Wed Jul 23, 8:44AM CDT
BioSyent Inc. ("BioSyent"
RX.VN: 7.570 (-0.250)
BioSyent Inc. (TSXV:RX) is the Subject of StockPotentials Report by eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com
Thomson Reuters ONE - Mon Jul 07, 6:28PM CDT
Vancouver, BC, July 7, 2014 - Toronto based eResearch has issued a StockPotentials report on BioSyent Inc. (TSXV:RX), a Toronto-based, growth oriented, independent pharmaceutical company. StockPotentials reports cover smaller companies eResearch believes would be primarily of interest to retail investors.
RX.VN: 7.570 (-0.250)
eResearch Issues Stock Potentials Report on BioSyent Inc.
ACCESSWIRE - Thu Jul 03, 10:51AM CDT
Toronto, ON / ACCESSWIRE / July 3, 2014 / eResearch Corporation provides Stock Potentials reports to highlight interesting prospects which may benefit from the exposure that eResearch can provide through its extensive electronic distribution network. This latest report features BioSyent Inc., a growth-oriented specialty pharmaceutical company, based in Toronto.
RX.VN: 7.570 (-0.250)